{"schema_version":"secwatch.filing_event.v1","accession":"0001517022-24-000019","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2024-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.460768+00:00","generated_at":"2026-06-06T03:22:08.202728+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Akebia extends separation dates for COO Dahan to June 28 and CLO Hadas to June 14","bullets":["COO Michel Dahan's separation extended from March 22 to June 28, 2024.","SVP/Chief Legal Officer Nicole Hadas separation extended from March 29 to June 14, 2024.","Both amendments signed on February 8, 2024; earlier retention agreements dated May 5, 2022.","Separations may further extend to Sept 22, 2024 upon certain specified events."],"urls":{"canonical":"https://secwatch.observer/filing/0001517022-24-000019","json":"https://secwatch.observer/filing/0001517022-24-000019.json","markdown":"https://secwatch.observer/filing/0001517022-24-000019.md","text":"https://secwatch.observer/filing/0001517022-24-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000151702224000019/0001517022-24-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000151702224000019/akba-20240208.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T03:22:08.202728+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"295a8227ed","claim":"Nicole R. Hadas departed as Senior Vice President, Chief Legal Officer and Secretary at Akebia Therapeutics, Inc..","evidence_excerpt":"On February 8, 2024, the Company and Ms. Hadas agreed to further extend the effective date of her separation to June 14, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517022/000151702224000019/0001517022-24-000019-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"separation extended"},{"label":"Role","value":"Senior Vice President, Chief Legal Officer and Secretary"}],"fact_type":"executive_change"},{"claim_id":"b26d937d11","claim":"Michel Dahan departed as Chief Operating Officer at Akebia Therapeutics, Inc..","evidence_excerpt":"On February 8, 2024, the Company and Mr. Dahan agreed to further extend the effective date of his separation to June 28, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517022/000151702224000019/0001517022-24-000019-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"separation extended"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}